Biogen Idec, Elan, Unilabs S.A. sales and marketing update

Unilabs said since March 2011 it used the Stratify JCV Antibody ELISA test to evaluate 30,000 patients receiving autoimmune drug Tysabri natalizumab. The anti-JCV antibody is associated with the development of progressive multifocal leukoencephalopathy (PML). Elan said that as of Dec. 31, 2011, there were about 64,400 patients on Tysabri, which is marketed by Biogen Idec and Elan to treat multiple sclerosis (MS) in the EU and to treat MS and Crohn's disease in the U.S. The humanized mAb against integrin alpha(4) had worldwide sales of more than $1.5 billion in 2011. ...